Bradley Wibrow1, F Eduardo Martinez2, Andrew Ford3, Erin Kelty4, Kevin Murray4, Kwok M Ho5, Edward Litton6, Erina Myers7, Matthew Anstey8. 1. Intensive Care Unit, Sir Charles Gairdner Hospital, University of WA, Perth, WA, Australia. Bradley.wibrow@health.wa.gov.au. 2. Intensive Care Unit, John Hunter Hospital, University of Newcastle, Newcastle, NSW, Australia. 3. Dept. of Psychiatry, Royal Perth Hospital, Perth, WA, Australia. 4. Centre for Applied Statistics, University of WA, Perth, WA, Australia. 5. Intensive Care Unit, Royal Perth Hospital, Medical School, University of Western Australia & Murdoch University, Perth, Australia. 6. St. John of God Hospital Subiaco, Intensive Care Unit, Fiona Stanley Hospital, Perth, WA, Australia. 7. Intensive Care Unit, Sir Charles Gairdner Hospital, Perth, WA, Australia. 8. Intensive Care Unit, Sir Charles Gairdner Hospital, Curtin University, Perth, WA, Australia.
Abstract
RATIONALE: Delirium is defined as acute organic brain dysfunction characterised by inattention and disturbance of cognition. It is common in the intensive care unit and is associated with poorer outcomes. Good quality sleep is important in the prevention and management of delirium. Melatonin is a natural hormone secreted by the pineal gland which helps in the regulation of the sleep-wake cycle. It is possible that melatonin supplementation in intensive care improves sleep and prevents delirium. METHODS AND DESIGN: The 'Prophylactic Melatonin for Delirium in Intensive Care' study is a multi-centre, randomised, double-blinded, placebo-controlled trial. The primary objective of this study is to determine whether melatonin given prophylactically decreases delirium in critically ill patients. A total of 850 ICU patients have been randomised (1:1) to receive either melatonin or a placebo. Participants were monitored twice daily for symptoms of delirium. RESULTS: This paper and the attached additional files describe the statistical analysis plan (SAP) for the trial. The SAP has been developed and submitted for publication before the database has been locked and before the treatment allocation has been unblinded. The SAP contains details of analyses to be undertaken, which will be reported in the primary and secondary publications. DISCUSSION: The SAP details the analyses that will be done to avoid bias coming from knowledge of the results in advance. This trial will determine whether prophylactic melatonin administered to intensive care unit patients helps decrease the rate and the severity of delirium. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry (ANZCTR) ACTRN1261600043647 , registration date: 06 April 2016. WHO Trial Number - U1111-1175-1814.
RCT Entities:
RATIONALE: Delirium is defined as acute organic brain dysfunction characterised by inattention and disturbance of cognition. It is common in the intensive care unit and is associated with poorer outcomes. Good quality sleep is important in the prevention and management of delirium. Melatonin is a natural hormone secreted by the pineal gland which helps in the regulation of the sleep-wake cycle. It is possible that melatonin supplementation in intensive care improves sleep and prevents delirium. METHODS AND DESIGN: The 'Prophylactic Melatonin for Delirium in Intensive Care' study is a multi-centre, randomised, double-blinded, placebo-controlled trial. The primary objective of this study is to determine whether melatonin given prophylactically decreases delirium in critically illpatients. A total of 850 ICU patients have been randomised (1:1) to receive either melatonin or a placebo. Participants were monitored twice daily for symptoms of delirium. RESULTS: This paper and the attached additional files describe the statistical analysis plan (SAP) for the trial. The SAP has been developed and submitted for publication before the database has been locked and before the treatment allocation has been unblinded. The SAP contains details of analyses to be undertaken, which will be reported in the primary and secondary publications. DISCUSSION: The SAP details the analyses that will be done to avoid bias coming from knowledge of the results in advance. This trial will determine whether prophylactic melatonin administered to intensive care unit patients helps decrease the rate and the severity of delirium. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry (ANZCTR) ACTRN1261600043647 , registration date: 06 April 2016. WHO Trial Number - U1111-1175-1814.
Entities:
Keywords:
Delirium; Intensive care unit; Melatonin; Sleep
Authors: Annemarieke de Jonghe; Barbara C van Munster; J Carel Goslings; Peter Kloen; Carolien van Rees; Reinder Wolvius; Romuald van Velde; Marcel Levi; Rob J de Haan; Sophia E de Rooij Journal: CMAJ Date: 2014-09-02 Impact factor: 8.262
Authors: Stuti J Jaiswal; Thomas J McCarthy; Nathan E Wineinger; Dae Y Kang; Janet Song; Solana Garcia; Christoffel J van Niekerk; Cathy Y Lu; Melissa Loeks; Robert L Owens Journal: Am J Med Date: 2018-05-03 Impact factor: 4.965
Authors: Sangeeta Mehta; Deborah Cook; John W Devlin; Yoanna Skrobik; Maureen Meade; Dean Fergusson; Margaret Herridge; Marilyn Steinberg; John Granton; Niall Ferguson; Maged Tanios; Peter Dodek; Robert Fowler; Karen Burns; Michael Jacka; Kendiss Olafson; Ranjeeta Mallick; Steven Reynolds; Sean Keenan; Lisa Burry Journal: Crit Care Med Date: 2015-03 Impact factor: 7.598
Authors: John W Devlin; Russel J Roberts; Jeffrey J Fong; Yoanna Skrobik; Richard R Riker; Nicholas S Hill; Tracey Robbins; Erik Garpestad Journal: Crit Care Med Date: 2010-02 Impact factor: 7.598
Authors: E W Ely; S Gautam; R Margolin; J Francis; L May; T Speroff; B Truman; R Dittus; R Bernard; S K Inouye Journal: Intensive Care Med Date: 2001-11-08 Impact factor: 17.440
Authors: Bradley Wibrow; F Eduardo Martinez; Erina Myers; Andrew Chapman; Edward Litton; Kwok M Ho; Adrian Regli; David Hawkins; Andrew Ford; Frank M P van Haren; Simon Wyer; Joe McCaffrey; Alan Rashid; Erin Kelty; Kevin Murray; Matthew Anstey Journal: Intensive Care Med Date: 2022-02-27 Impact factor: 17.440